The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

Conditions: High Titers of Anti-HLA Antibody (MFI ≥5000) Interventions: Combination Product: Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG Sponsors: Anhui Provincial Hospital Not yet recruiting

Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials